Cue Biopharma, Inc. (CUE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing injectable therapeutics to modulate disease-specific T cells for autoimmune diseases and cancer. The company operates as a single reporting segment. This report covers the quarterly period ended June 30, 2025. As of this date, the company had 76,845,904 shares of Common Stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Collaboration Revenue | $2.95 million | $3.37 million | $4.38 million |
| Net Loss | $(8.48) million | $(20.74) million | $(22.52) million |
| Loss Per Share (Basic & Diluted) | $(0.09) | $(0.24) | $(0.45) |
| Cash and Cash Equivalents | $27.49 million (as of June 30, 2025) | ||
| Total Assets | $40.71 million (as of June 30, 2025) | ||
| Total Liabilities | $22.55 million (as of June 30, 2025) | ||
| Stockholders' Equity | $18.16 million (as of June 30, 2025) | ||
| Long-Term Debt (Current Portion) | $2.42 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue: Collaboration revenue increased by $0.3 million in Q2 2025 compared to Q2 2024, driven by the new Boehringer Ingelheim (BI) agreement. However, YTD revenue decreased by $1.0 million compared to YTD 2024 due to the timing of revenue recognition from the terminated Ono agreement versus the new BI agreement.
- Expenses: Total operating expenses decreased by $1.5 million in Q2 2025 and $3.1 million YTD 2025 compared to the prior year periods. This reduction was primarily due to lower clinical trial costs for the CUE-100 series (shifting to survival monitoring) and reduced employee compensation.
- Financing Activity: The company raised significant capital in the first half of 2025. In April 2025, it completed an underwritten public offering of common stock, warrants, and pre-funded warrants, netting approximately $18.0 million. Additionally, it raised $0.8 million via its At-The-Market (ATM) program.
- Debt: The company repaid $2.0 million of its term loan principal during the six months ended June 30, 2025. The remaining term loan balance is due in full on December 1, 2025.
Guidance, Outlook, and Risks
- Going Concern: The company has raised substantial doubt regarding its ability to continue as a going concern. Management estimates current cash resources will fund operations only into the second quarter of 2026. Additional capital is required to continue operations.
- Strategic Focus: The company is prioritizing the development of CUE-401 (autoimmune) and the CUE-500 series. CUE-501 has been licensed to Boehringer Ingelheim. The company is seeking collaborations for its oncology assets (CUE-101 and CUE-102).
- Key Agreements:
- Boehringer Ingelheim (BI): Entered into a collaboration in April 2025 for CUE-501. Received a $10.1 million upfront payment (net of withholding tax). Potential for up to $345 million in milestones.
- Ono Pharmaceutical: Terminated the collaboration agreement in March 2025; Cue retained all rights to CUE-401.
- LG Chem: Regained rights to the CUE-101 program in the LG Chem territory in March 2025.
- Risk Factors:
- Nasdaq Delisting: Received a deficiency letter on May 12, 2025, for failing to maintain the $1.00 minimum bid price. The company has 180 days (until November 10, 2025) to regain compliance.
- Trade Policy: Potential adverse impacts from new U.S. tariffs and trade restrictions on pharmaceutical imports.
- Capital Markets: Volatility may hinder the ability to raise necessary funds on acceptable terms.
Investor Verification Checklist
- Verify the timeline and sufficiency of future financing plans to bridge the gap beyond Q2 2026.
- Monitor the stock price to ensure compliance with Nasdaq's $1.00 minimum bid requirement by November 10, 2025.
- Review the status of the $1.9 million German withholding tax receivable related to the BI upfront payment.
- Assess the progress of the CUE-401 IND application, targeted for filing in Q2 2026.
- Confirm the repayment schedule and covenants for the remaining term loan due December 1, 2025.